Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a solid tumor that has been confirmed by a biopsy or other lab test.
- You are planning to get at least 2 rounds of chemotherapy that has a high or medium risk of causing a serious drop in white blood cells.
- You must have a good performance status (ECOG score 0-2), meaning you are able to care for yourself and do everyday activities.
- Your blood counts and organ function (liver, kidneys, heart) must be within certain ranges before starting the study.
- You cannot be pregnant or breastfeeding, and if you can have children, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
This trial tests a medication (Efbemalenograstim alfa) that helps boost your white blood cell counts during chemotherapy for ovarian or cervical cancer. It aims to reduce the risk of serious infections (febrile neutropenia) while you receive standard treatment with paclitaxel plus carboplatin or cisplatin, with or without bevacizumab.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Hear when a new Primary/Secondary Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.